tiprankstipranks
Advertisement
Advertisement

OVID Stock Latest News

Ovid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy Rating
RatingsOvid Therapeutics: Undervalued KCC2 Platform and Upcoming OV4071 Catalyst Support Buy Rating
3d ago
OVID
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
PremiumThe Fly
Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright
3d ago
OVID
3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts
5d ago
IVA
OVID
Ovid Therapeutics price target raised to $7 from $5 at Wedbush
PremiumThe Fly
Ovid Therapeutics price target raised to $7 from $5 at Wedbush
23d ago
OVID
Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
PremiumCompany Announcements
Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines
23d ago
OVID
Ovid Therapeutics price target raised to $5 from $3 at Roth Capital
PremiumThe FlyOvid Therapeutics price target raised to $5 from $3 at Roth Capital
24d ago
OVID
Ovid Therapeutics: Advancing OV329 Pipeline, De‑Risked Differentiation, and Strong Cash Runway Support Buy Rating
Premium
Ratings
Ovid Therapeutics: Advancing OV329 Pipeline, De‑Risked Differentiation, and Strong Cash Runway Support Buy Rating
25d ago
OVID
Midday Fly By: General Mills reports downbeat Q3, Macy’s reports Q4 beat
Premium
The Fly
Midday Fly By: General Mills reports downbeat Q3, Macy’s reports Q4 beat
25d ago
M
CF
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention
PremiumTipRanks Newswire
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention
25d ago
CING
OVID
Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline
PremiumCompany Announcements
Ovid Therapeutics Raises Capital to Expand Epilepsy Pipeline
25d ago
8K
OVID
Ovid Therapeutics announces Phase 1 clearance for OV4071
PremiumThe Fly
Ovid Therapeutics announces Phase 1 clearance for OV4071
25d ago
OVID
Ovid Therapeutics reports Q4 EPS 6c, consensus (10c)
PremiumThe Fly
Ovid Therapeutics reports Q4 EPS 6c, consensus (10c)
25d ago
OVID
Ovid Therapeutics sees cash runway into late 2028
PremiumThe FlyOvid Therapeutics sees cash runway into late 2028
25d ago
OVID
Ovid Therapeutics announces OV239 data, indication expansion
Premium
The Fly
Ovid Therapeutics announces OV239 data, indication expansion
25d ago
OVID
Ovid Therapeutics prices 19.15M shares at $2.01 in private placement
Premium
The Fly
Ovid Therapeutics prices 19.15M shares at $2.01 in private placement
25d ago
OVID
OVID Earnings this Week: How Will it Perform?
PremiumPre-Earnings
OVID Earnings this Week: How Will it Perform?
29d ago
OVID
CWAN, HTBK, OVID, MCFT, WHWK Trending With Analysts
PremiumWeekend Updates
CWAN, HTBK, OVID, MCFT, WHWK Trending With Analysts
4M ago
CWAN
HTBK
Ovid Therapeutics initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Ovid Therapeutics initiated with an Outperform at LifeSci Capital
4M ago
OVID
Ovid Therapeutics: Positive KCC2 Platform Progress and Underappreciated Pipeline Optionality Support Reiterated Buy Rating
PremiumRatings
Ovid Therapeutics: Positive KCC2 Platform Progress and Underappreciated Pipeline Optionality Support Reiterated Buy Rating
4M ago
OVID
Ovid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating
PremiumRatingsOvid Therapeutics: De-Risked KCC2 Platform and OV329 as Key Drivers of Long-Term Growth Support Buy Rating
4M ago
OVID
Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward
Premium
Ratings
Ovid Therapeutics: Early KCC2 Proof-of-Mechanism and High-Potency OV4071 Pipeline Support Buy Rating and Attractive Long-Term Risk‑Reward
4M ago
OVID
Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data
Premium
Company Announcements
Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data
4M ago
8K
OVID

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >